An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study

Main Article Content

D Thaci
K Papp
K Gordon
A Morita
M Gooderham
P Foley
E Alemano
R Kisa
Y Elbez
H Ren
S Banerjee

Keywords

psoriasis, tyrosine kinase 2 inhibitor

Abstract

Abstract not available.

References

1. Mahil SK et al. Semin Immunopathol. 2016;38:11-27.

2. Armstrong AW et al. PLoS One. 2012;7:e52935.

3. Dubertret L et al. Br J Dermatol. 2006;155:729-736.

4. Finlay AY, Khan GK. Clin Exp Dermatol. 1994;19:210-216.

5. Tokarski JS et al. J Biol Chem. 2015;290:11061-11074.

6. Gillooly K et al. Arthritis Rheumatol. 2016;68(suppl 10):abstract 11L.

7. Harden JL et al. J Autoimmun. 2015;64:66-73.

8. Yao Y et al. PLoS One. 2008;3:e2737.

9. Papp K et al. N Engl J Med. 2018;379:1313-1321.

10. Hongbo Y et al. J Invest Dermatol. 2005;125:659-664.